Company intelligence / Profile preview

Probiomics

Sydney, NSW, Australiatga.gov.au ↗

Ownership: Private
Development stage: Commercial

Overview

The Australian entity’s main asset was HI‑164OV, a vaccine targeting COPD that completed a Phase IIa trial showing reduced hospital admissions and was in a large Phase IIb trial as of April 2012. The company also developed OTC probiotic products based on the Lactobacillus fermentum PCC® strain.[3][2][5]

Therapeutic areas: OtherInfectious Diseases
Industry: Biotech

Drug pipeline

4 assets

PROTRACT

Commercial

Indications: Diarrhea

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Probiomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Probiomics.

Explore the full profile